Skip to main
BNTC

BNTC Stock Forecast & Price Target

BNTC Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 25%
Buy 75%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Benitec Biopharma Inc. shows a promising outlook primarily due to its innovative approach in developing BB-301, a therapeutic for Oculopharyngeal Muscular Dystrophy, with interim clinical results indicating a 100% responder rate and the potential for long-term improvement in patient outcomes. The recent data suggests increased interactions with regulators that could lead to accelerated market entry, alongside favorable pricing opportunities reflecting the treatment's value thanks to demonstrated efficacy. Additionally, Benitec's robust financial position, with $94.5 million in cash and cash equivalents, positions the company well to support the ongoing development and potential regulatory pathways for BB-301.

Bears say

Benitec Biopharma reported a net loss of $0.21 per share for the first quarter of fiscal 2026, a smaller loss than anticipated, primarily attributed to a higher-than-expected number of shares outstanding. The company faces significant risks, including the potential for slower-than-expected clinical trial progress for its BB-301 treatment, negative trial data, and challenges in establishing a regulatory approval pathway. Additionally, there are concerns regarding slow market adoption and long-term dilution risks, which contribute to a cautious financial outlook for the company.

BNTC has been analyzed by 4 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 75% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Benitec Biopharma Limited Sponsored ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Benitec Biopharma Limited Sponsored ADR (BNTC) Forecast

Analysts have given BNTC a Buy based on their latest research and market trends.

According to 4 analysts, BNTC has a Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Benitec Biopharma Limited Sponsored ADR (BNTC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.